SEED Therapeutics announced at its Monday, October 23, 2023 Targeted Protein Degradation, TPD, Think Tank symposium that it had successfully discovered a ST-00937, a new chemical entity, NCE, molecular glue that has already achieved IND Candidate status and will be advanced for the treatment of cancers in SEED’s first IND filing, as early as 2024. SEED is a subsidiary of BeyondSpring. Dr. James Tonra, SEED President, and Chief Scientific Officer, said, “Preclinical data over the last two to three years has uncovered new and important cancer indications for agents that can inhibit or degrade the RNA splicing factor RBM39, but clinical activity in these new indications is minimal or absent.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BYSI:
- SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
- SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
- BeyondSpring receives noncompliance notification from Nasdaq
- BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
- BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
